Susan Hasty, Publisher
Table of Contents . . . November 7th, 2002
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Blood Weekly | Other Publications
Blood Testing - RIBA-3 HCV immunoassay best choice for blood product screening
Stem Cell Transplantation - Peripheral blood grafts linked to improved survival rates
Cord Blood - Molecular and serological typing methods both needed for best results
Creutzfeldt Jakob Disease - Hopes rise for test to spot vCJD
Stem Cell Transplantation - Expanded clonal T cell levels predict favorable response to photopheresis treatment
Adenovirus - Graft T-cell depletion, alemtuzumab use linked to post-transplant adenovirus infection
Anticoagulation - Study finds direct thrombin inhibitor safe, effective in HIT patients
Blood Diagnostics - Military orders blood analysis systems; FDA clears phosphate assay
Blood Supply - FDA clearance granted for blood collection system
End-Stage Renal Disease - European approval of Fosrenol not expected in 2002
End-Stage Renal Disease - Hepatitis A vaccine protects hemodialysis patients from viral infection
Finance - Record 3Q 2002 sales reported from cord blood program
HIV Management - Company receives FDA approval for Versant HIV bDNA viral load system
Hemodialysis - Customers advised to suspend use of certain bloodlines pending investigation
Malaria - Newly discovered peptide induces protection against malaria
Mergers and Acquisitions - New company created by merger
Nucleic Acid Testing - Trading begins on Nasdaq after spin-off from Chugai
Performance-Enhancing Drugs - Officials worried about 'untraceable' blood-doping drug
Transfusion Medicine - Larger blood reserves needed for aging population
Transplant Medicine - Phase I clinical trial results reported for antirejection drug
West Nile Virus - EPA will bypass pesticide regulations to fight outbreaks
West Nile Virus - NASA researchers developing tools to help track and predict epidemiology
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.